Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy

Liudmila V SPIRINA; Irina V KONDAKOVA; Natalia V TARASENKO; Elena M SLONIMSKAYA; Evgeny A USYNIN; Alexey K GORBUNOV; Zahar A YURMAZOV; Svetlana Yu CHIGEVSKAYA

doi:10.3779/10.3779/j.issn.1009-3419.2018.01.09

Article Tools

Indexing metadata

How to cite item

Finding References

Review policy

Email this article (Login required)

Related Items

Show all

About The Authors

Liudmila V SPIRINA
Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia;Department of Biochemistry and Molecular Biology, Siberian State Medical University, Tomsk, Russia

Irina V KONDAKOVA
Laboratory of Tumor Biochemistry, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Natalia V TARASENKO
Department of Medical Genetics, Siberian State Medical University, Tomsk, Russia;Laboratory of Population Genetics, Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Elena M SLONIMSKAYA
Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia;Department of Oncology, Siberian State Medical University, Tomsk, Russia

Evgeny A USYNIN
Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Alexey K GORBUNOV
Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Zahar A YURMAZOV
Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Svetlana Yu CHIGEVSKAYA
Surgical Department, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Russia

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy

Liudmila V SPIRINA, Irina V KONDAKOVA, Natalia V TARASENKO, Elena M SLONIMSKAYA, Evgeny A USYNIN, Alexey K GORBUNOV, Zahar A YURMAZOV, Svetlana Yu CHIGEVSKAYA

Abstract

Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.

DOI: 10.3779/j.issn.1009-3419.2018.01.09

Full Text: PDF HTML

0 Citation
Alert me when cited by CSCD.

This work is licensed under a Creative Commons Attribution 3.0 License.

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy

Abstract

Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy—— AKT/m-TOR Pathway and Resistance to Cancer Therapy